Perosphere Pharmaceuticals

NCT03288454

Phase 2, Completed, 2017, 60 people, 20 Sept 2017, clinicaltrials.gov

NCT02206087

Phase 1/2, Completed, 2014, 60 people, 1 Aug 2014, clinicaltrials.gov